CTU: A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

  • Zhang, Alison (Primary Chief Investigator)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleRC48G001
Effective start/end date11/10/2318/07/28